TELA Bio, Inc. (TELA)
Stock Price:
$15.16 USD
-0.60 (-3.81%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
218.52M |
| Revenue (ttm) |
16.07M |
| Net Income (ttm) |
-27.50M |
| Shares Out |
14.41M |
| EPS (ttm) |
-3.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$15.16 |
| Previous Close |
$15.76 |
| Change ($) |
-0.60 |
| Change (%) |
-3.81% |
| Day's Open |
15.49 |
| Day's Range |
14.92 - 15.49 |
| Day's Volume |
15,932 |
| 52-Week Range |
5.25 - 23.55 |
More Stats
| Market Cap |
218.52M |
| Enterprise Value |
163.57M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.41M |
| Float |
9.14M |
| EPS (basic) |
35.78 |
| EPS (diluted) |
-3.75 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
172,472 |
| Short Ratio |
3.76 |
| Short % of Float |
1.89% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
13.60 |
| PB Ratio |
3.62 |
| Revenue |
16.07M |
| Operating Income |
-21.35M |
| Net Income |
-27.50M |
| Free Cash Flow |
n/a |
| Net Cash |
54.95M |
| Net Cash / Share |
3.81 |
| Gross Margin |
59.59% |
| Operating Margin |
-132.84% |
| Profit Margin |
-171.10% |
| FCF Margin |
n/a |
| ROA |
-21.49% |
| ROE |
-96.61% |
| ROIC |
-54.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.75*
(30.28% upside)
Low
17.0
Current: $15.16
High
24.0
Target: 19.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 15.45 | 8.27 | 4.25 |
| Revenue Growth | 86.68% | 94.91% | - |
| Gross Profit | 9.27 | 2.94 | 2.53 |
| Operating Income | -19.16 | -17.78 | -16.92 |
| Net Income | -22.43 | -21.09 | -21.33 |
| Shares Outstanding | 1.77 | 0.29 | 0.29 |
| Earnings Per Share | -17.10 | -101.41 | -93.26 |
| Operating Cash Flow | -25.52 | -19.92 | -16.37 |
| Capital Expenditures | -0.20 | -0.06 | -0.10 |
| Free Cash Flow | -25.72 | -19.98 | -16.47 |
| Cash & Equivalents | 54.59 | 17.28 | 11.37 |
| Total Debt | 30.24 | 29.73 | 4.52 |
| Net Cash / Debt | 24.34 | -12.46 | 6.86 |
| Assets | 67.92 | 27.23 | 15.53 |
| Liabilities | 36.96 | 40.94 | 12.35 |
| Book Value | 30.96 | -138 | -108 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
TELA Bio, Inc. |
| Country |
United States |
| Employees |
89 |
| CEO |
Antony Koblish |
Stock Information
| Ticker Symbol |
TELA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: TELA |
| IPO Date |
November 8, 2019 |
Description
TELA Bio, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.